Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Real-world Prescribing Patterns of Antifungal drugs in Patients with Aspergillosis

국내 아스페르길루스증에 대한 항진균제 처방 현황

  • Sangsu Youm (College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University) ;
  • Pusoon Chun (College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University)
  • 염상수 (인제대학교 약학대학 인제약학연구소) ;
  • 천부순 (인제대학교 약학대학 인제약학연구소)
  • Received : 2023.05.01
  • Accepted : 2023.06.10
  • Published : 2023.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Globally, the number of patients with aspergillosis is increasing, and the mortality rate remains high. This study aimed to investigate prescribing patterns of antifungal drugs for patients with aspergillosis in South Korea using real-world data. Methods: This retrospective cross-sectional study was performed using National Patient Sample (NPS) data collected by the Health Insurance Review and Assessment Service (HIRA) during 2011-2020. The use of antifungal drugs in patients with aspergillosis was investigated. Results:A total of 1374 patients were identified: 333 patients with invasive pulmonary aspergillosis (IPA) (24.2%), 436 patients with other PA (31.7%), 73 patients with other forms of aspergillosis (5.3%), and 532 patients with unspecified aspergillosis (38.7%). The odds of receiving an antifungal prescription were higher for IPA than for other PA (aOR, 0.233; p<0.001), and higher for hematologic malignancies than for respiratory disorders other than cancer or infections (aOR, 10.018; p<0.001). During each hospitalization period, 56.1% (97/173) and 6.4% (11/173) of IPA hospitalizations received voriconazole and itraconazole monotherapy, respectively, whereas 44.3% (27/61) and 27.9% (17/61) of other PA hospitalizations received itraconazole and voriconazole monotherapy, respectively. Among outpatients with IPA, 67.5% (85/126) and 26.2% (33/126) received voriconazole and itraconazole alone, respectively, whereas among outpatients with other PA, 86.1% (68/79) and 12.7% (10/79) received itraconazole and voriconazole alone, respectively, during the year. Conclusion: In Korea, voriconazole monotherapy was preferred in IPA inpatients, and itraconazole monotherapy was preferred in other PA inpatients. In the ambulatory care settings for IPA and other PA, itraconazole monotherapy was preferred.

Keywords

Acknowledgement

This study was performed using HIRA-NPS 2011-2020 S20220518007), but the results of this study have no concern with the Ministry of Health and Welfare and HIRA.

References

  1. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999;12(2):310-50.  https://doi.org/10.1128/CMR.12.2.310
  2. Khan AAH, Karuppayil SM. Fungal pollution of indoor environments and its management. Saudi J Biol Sci 2012;19(4):405-26.  https://doi.org/10.1016/j.sjbs.2012.06.002
  3. Seyedmousavi S, Guillot J, Arne P, et al. Aspergillus and aspergilloses in wild and domestic animals: a global health concern with parallels to human disease. Med Mycol 2015;53(8):765-97.  https://doi.org/10.1093/mmy/myv067
  4. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multinational prevalence of fungal diseases-estimate precision. J Fungi (Basel) 2017;3(4):57. 
  5. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;63(4):e1-60.  https://doi.org/10.1093/cid/ciw326
  6. Husain S, Camargo JF. Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33(9):e13544. 
  7. Tudesq JJ, Peyrony O, Lemiale V, Azoulay E. Invasive pulmonary aspergillosis in nonimmunocompromised hosts. Semin Respir Crit Care Med 2019;40(4):540-7.  https://doi.org/10.1055/s-0039-1696968
  8. Jenks JD, Hoenigl M. Treatment of aspergillosis. J Fungi (Basel) 2018;4(3):98. 
  9. Ullmann AJ, Aquado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24 Suppl 1:e1-38.  https://doi.org/10.1016/j.cmi.2018.01.002
  10. Tutar N, Metan G, Koc AN, et al. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Multidiscip Respir Med 2013;8(1):59. 
  11. Vallabhaneni S, Benedict K, Derado G, Mody RK. Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000-2013 external icon. Open Forum Infect Dis 2017;4(1):ofw268. 
  12. National Health Insurance Service. Annual report on health insurance statistics. Available from https://www.nhis.or.kr/nhis/together/wbhaec06300m01.do. Accessed June 8, 2023. 
  13. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014;36:e2014008. 
  14. Healthcare Bigdata Hub. Patient sample data guide. Available from https://opendata.hira.or.kr/op/opc/selectPatDataAplInfoView.do. Accessed June 10, 2022 
  15. Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016;47(1):45-68.  https://doi.org/10.1183/13993003.00583-2015
  16. DATA.GO.KR. HIRA_Drug Price Master_Medicine Main Ingredient. Available from https://www.health.kr/drug_info/basedrug/main_ingredient.html. Accessed June 10, 2022. 
  17. Tarka P, Nitsch-Osuch A, Gorynski P, Tyszko P, Bogdan M, Kanecki K. Epidemiology of pulmonary aspergillosis in hospitalized patients in Poland during 2009-2016. Adv Exp Med Biol 2019;1160:73-80.  https://doi.org/10.1007/5584_2019_347
  18. Maitre T, Cottenet J, Godet C, et al. Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis. Eur Respir J 2021;58(2):2003345. 
  19. KOSIS. Status of hospitals by national region. Available from https://kosis.kr/statHtml/statHtml.do?orgId=354&tblId=DT_MIRE01. Accessed August 10, 2022. 
  20. Ledoux MP, Guffroy B, Nivoix Y, Simand C, Herbrecht R. Invasive Pulmonary Aspergillosis. Semin Respir Crit Care Med 2020;41(1):80-98.  https://doi.org/10.1055/s-0039-3401990
  21. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15.  https://doi.org/10.1056/NEJMoa020191
  22. Herbrecht R, Patterson TF, Slavin MA, et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis 2015;60(5):713-20.  https://doi.org/10.1093/cid/ciu911
  23. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34(5):563-71.  https://doi.org/10.1086/324620
  24. Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97(2):135-44.  https://doi.org/10.1016/0002-9343(94)90023-X
  25. Health Insurance Review and Assessment Service. Drug benefit list. Available from https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000&brdScnBltNo=4&brdBltNo=1623. Accessed August 10, 2022.